US Patent 5,780,676: Scope, Claims, Expiration, and RXR Agonist Patent Landscape

US Patent 5,780,676 covers pharmaceutical compositions, therapeutic methods, and combination therapies involving compounds that preferentially activate retinoid X receptors, or RXRs, over retinoic acid receptors, or RARs. The patent issued July 14, 1998, and its ordinary 17-year patent term expired July 14, 2015. The patent therefore has no remaining enforceable US term, although it remains relevant to historical freedom-to-operate analysis, validity precedent, and the development of later RXR agonists.

The claims divide into four groups:

A defined set of ten retinoid compounds and their salts, esters, and amides.
Functional claims covering compounds more potent at RXR than RAR in a co-transfection assay.
Method-of-treatment claims covering lipid, dermatologic, oncologic, inflammatory, autoimmune, and endocrinologic uses.
Combination claims pairing an RXR-selective compound with a second antiproliferative or cell-cycle-modulating agent.

The patent is closely associated with the RXR agonist field that produced bexarotene, marketed as Targretin. The supplied claims do not expressly name bexarotene, and claim coverage must therefore be assessed by chemical identity and functional limitations rather than by product name alone.

What does US Patent 5,780,676 cover?

US 5,780,676 covers compounds and therapeutic uses linked to selective RXR activation. RXRs are nuclear receptors that regulate transcription through heterodimeric complexes with receptors including RAR, thyroid hormone receptor, vitamin D receptor, and peroxisome proliferator-activated receptor. The claimed pharmacology is not simply retinoid activity. It is preferential RXR activation relative to RAR activation.

Patent identification and status

Field	Information
Patent	US 5,780,676
Issue date	July 14, 1998
Technology	RXR-selective retinoids and therapeutic uses
Primary assignee associated with the patent record	Ligand Pharmaceuticals Incorporated
Patent term	17 years from grant under the pre-URAA term applicable to the application
Ordinary expiration	July 14, 2015
Current enforceability	Expired
Drug class	Retinoid X receptor agonists, or rexinoids
Commercial product most closely associated with the field	Bexarotene, marketed as Targretin
FDA product types	Capsules and topical gel

The patent’s expiration ended the ability to obtain damages or injunctive relief for post-expiration US infringement. Expiration did not invalidate the patent historically, and it did not eliminate the relevance of its disclosure to later patentability analyses.

How are the claims structured?

The patent contains 23 claims. The claims can be analyzed by legal category and scope.

Claim 1: Defined chemical compounds and pharmaceutical compositions

Claim 1 is a composition claim directed to a pharmaceutical vehicle containing one or more compounds selected from a list of ten named retinoid structures, together with pharmaceutically acceptable esters, amides, and salts.

The listed compounds include:

Branched-chain polyene carboxylic acids.
Cyclohexenyl-substituted retinoid analogs.
Cyclohexyl, cyclopropyl, and phenyl derivatives.
Tetramethyl- and pentamethyl-tetrahydronaphthyl compounds.
Compounds with defined 2E,4E,6Z or 2E,4E stereochemistry.

The claim is limited by both chemical identity and pharmaceutical use. A molecule outside the listed structures would not infringe claim 1 merely because it activates RXR. A compound must fall within one of the listed structures or within the specified ester, amide, or salt forms.

The vehicle limitation is broad. The claim covers compositions suitable for:

Enteral administration.
Parenteral administration.
Topical administration.

The claim does not require a particular dosage, concentration, excipient, release profile, particle size, container, or formulation technology. The principal limitation is the identity of the active ingredient.

Claims 2-6: Therapeutic processes defined by receptor selectivity

Claims 2 through 6 cover therapeutic administration of a compound that is more potent at activating RXR than RAR in a co-transfection assay.

The claimed medical fields include:

Lipid metabolism and lipid homeostasis.
Fatty-acid metabolism.
Hyperlipidemia and plasma HDL levels.
Dermatologic disorders and keratinization disorders.
Acne, psoriasis, aging, and wrinkling.
Autoimmune and inflammatory diseases.
Malignant-cell development and premalignant lesions.
Programmed cell death.
Endocrinologic processes.
Acute promyelocytic leukemia.
Mammary, prostate, lung, bladder, skin, and aerodigestive cancers.
Sarcomas and leukoplakias.

Claims 3 and 4 narrow the receptor-selectivity requirement to compounds at least three times or at least five times more potent at RXR than RAR. Claims 5 and 6 provide more detailed disease and therapeutic categories.

These claims are method claims rather than composition-of-matter claims. They require administration to a subject or treatment of a condition. A compound supplier or manufacturer would not necessarily infringe solely by making the compound unless the relevant method-of-use facts were established.

Claims 7-12: Broad composition claims

Claims 7 through 12 cover pharmaceutical compositions containing compounds that preferentially activate RXR over RAR.

The claims do not restrict the composition to the ten compounds listed in claim 1. Their functional language potentially reaches a wider class of compounds, provided the compound satisfies the assay-based selectivity requirement.

Claim 10 is particularly broad because it covers a composition containing a compound that:

Modulates a process mediated by RXR; and
Selectively activates one or more RXRs in preference to RARs.

Claims 8, 9, 11, and 12 impose threefold and fivefold selectivity thresholds.

The practical scope of these claims depends on the construction of:

“More potent.”
“Selectively activates.”
“In preference to.”
“Co-transfection assay.”
“Modulates a process mediated by” RXR.

Claims 13-18: Methods of modulating RXR-mediated processes

Claims 13 through 18 cover methods of causing an RXR-mediated process to occur in the presence of a preferential RXR activator, or administering that compound to a mammalian subject.

These claims extend beyond treatment of named diseases and include biological processes such as:

Lipid metabolism.
Lipid homeostasis.
Hyperlipidemia.
Skin-related processes.
Fatty-acid metabolism.
Malignant-cell development.
Premalignant lesions.
Programmed cell death.
Endocrinologic processes.
AP-1 metabolism.

Claims 14, 15, 17, and 18 impose threefold and fivefold selectivity thresholds.

The claims are functional and technically broad. Their enforceability would depend on proving that the accused compound meets the receptor activity requirement and that the accused conduct falls within the claimed therapeutic or biological process.

Claims 19-23: Combination treatment and synergy

Claim 19 covers a composition containing:

A compound more potent at activating RXR than RAR; and
A second compound that affects cellular proliferation or acts as a cell-cycle modulator.

Claim 23 identifies four examples of the second agent:

Interferon.
Methotrexate.
Fluorouracil.
ARA-C, commonly referring to cytarabine.

Claim 22 requires more than simple coadministration. It requires that the combined inhibition of cellular proliferation at a given concentration exceed the additive effect of the two compounds used separately at that concentration.

This is a synergy limitation. It creates a higher evidentiary burden than a claim requiring only the presence of two active agents. A party asserting infringement would need to establish the relevant concentration, the individual effects, the combined effect, and the methodology used to determine that the result is greater than additive.

What compounds are expressly protected by claim 1?

The compounds identified in claim 1 are specific rexinoid structures rather than a general chemical genus. The structures are characterized by conjugated carboxylic-acid systems, substituted cyclohexenyl groups, and tetrahydronaphthyl groups.

Structural group	Defining characteristics
Aliphatic polyene acids	3-methyl and 7-ethyl, propyl, isopropyl, trimethyl, or tert-butyl substitution
Aromatic and cyclohexyl derivatives	2-substituted phenyl or cyclohexyl groups connected to a trimethylcyclohexenyl moiety
Cyclopropyl derivative	Cyclopropyl-substituted conjugated diene acid
Tetrahydronaphthyl derivatives	Tetramethyl- or pentamethyl-substituted tetrahydronaphthyl groups
Permitted derivatives	Pharmaceutically acceptable esters, amides, and salts

Bexarotene has a different chemical description: 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid. It is a selective RXR agonist, but the chemical name does not appear in the supplied text of claim 1. Whether bexarotene falls within any broader claim depends on the patent’s specification, prosecution history, and construction of the functional claims, not on claim 1 alone.

How broad are the functional RXR claims?

The functional claims are broader than the structure-specific claim, but they contain technical limitations that constrain their reach.

The co-transfection assay limitation

The claims require the compound to be more potent at activating RXR than RAR in a co-transfection assay. A typical co-transfection assay introduces:

An RXR or RAR expression construct.
A reporter gene controlled by a receptor-responsive promoter.
The test compound.
A cellular system capable of producing a measurable transcriptional response.

The result is generally expressed through a potency value such as EC50, a maximal transcriptional response, or an activity ratio. The patent language focuses on relative potency rather than a universal absolute activity threshold.

This limitation provides a measurable technical boundary, but it also creates claim-construction and proof issues:

The exact receptor isoform may matter.
RXR alpha, RXR beta, and RXR gamma may respond differently.
RAR alpha, RAR beta, and RAR gamma may produce different comparative results.
Assay cells, reporter constructs, expression levels, incubation periods, and normalization methods can affect the ratio.
“More potent” can differ from “greater maximal efficacy.”
A compound can be a partial agonist at one receptor and a full agonist at another.

Threefold and fivefold selectivity

Claims 3, 4, 8, 9, 11, 12, 14, 15, 17, 18, 20, and 21 impose explicit threefold or fivefold selectivity thresholds.

These dependent claims are narrower than the unqualified “more potent” claims. They may be easier to test but require a greater separation between RXR and RAR activity. Assay variability becomes material where a measured ratio is close to three or five.

Selective activation versus receptor modulation

Claim 10 also refers to a compound that modulates an RXR-mediated process and selectively activates RXR in preference to RAR. This language is distinct from a claim requiring only receptor binding. A compound may bind RXR without activating it, and it may modulate an RXR-mediated pathway indirectly without being a direct agonist.

The claims therefore focus on functional receptor pharmacology rather than merely chemical class membership.

What is the relationship to bexarotene and Targretin?

Bexarotene is the best-known commercial RXR agonist associated with this patent field. The FDA approved Targretin capsules in 1999 for cutaneous manifestations of AIDS-related Kaposi’s sarcoma after failure of at least one prior systemic therapy. The FDA later approved Targretin gel for topical treatment of cutaneous lesions in patients with cutaneous T-cell lymphoma involving persistent or recurrent disease after other therapies [2].

Bexarotene has the following profile:

Attribute	Bexarotene
Brand	Targretin
Active ingredient	Bexarotene
Mechanism	Selective RXR agonist
Dosage forms	Oral capsules and topical gel
Initial FDA approval	1999
Major approved use	Cutaneous T-cell lymphoma and related dermatologic oncology indications
Key safety issues	Hyperlipidemia, hypothyroidism, pancreatitis risk, and laboratory monitoring
Patent relevance	RXR-selective compound and use patents, including the 5,780,676 landscape

The FDA label describes bexarotene as a retinoid that selectively activates RXR nuclear receptor subtypes. It also requires lipid monitoring and management of treatment-related metabolic effects [2].

The commercial product does not establish infringement of every claim in US 5,780,676. The relevant analysis would compare:

The exact bexarotene structure with claim 1.
Bexarotene’s receptor activity profile with the functional limitations in claims 2-18.
The marketed formulation with claims 1 and 7-12.
Any combination regimen with claims 19-23.

When did US Patent 5,780,676 lose exclusivity?

The patent lost enforceable exclusivity on July 14, 2015, 17 years after issuance. The patent was issued under the pre-URAA patent-term regime applicable to the underlying application. No current Orange Book exclusivity can arise from an expired patent.

Patent expiration is separate from FDA regulatory exclusivity. FDA exclusivity may block approval of a competing application for a defined period even without a patent. For Targretin, the relevant regulatory exclusivity periods have also expired.

What was the Orange Book status of the patent?

The Orange Book historically listed patents associated with approved bexarotene products. Orange Book listings are product-specific. A patent may be listed for capsules but not gel, or for one approved use but not another, depending on the patent certification and FDA listing record.

The Orange Book framework requires an ANDA applicant to address listed patents through:

Paragraph I certification, if no patent information is listed.
Paragraph II certification, if the patent has expired.
Paragraph III certification, if the applicant will wait until patent expiration.
Paragraph IV certification, if the applicant asserts that the patent is invalid, unenforceable, or not infringed [3].

Because US 5,780,676 expired in 2015, a current applicant would not face a live Paragraph IV risk based on that patent alone. The patent could have generated Paragraph IV litigation before expiration, but it no longer blocks FDA approval through a remaining patent term.

Were there Paragraph IV challenges and patent litigation?

Bexarotene’s generic-entry history involved patent certifications and litigation concerning Targretin-related patents. The relevant commercial disputes centered on whether generic products could enter before expiration of the listed patents and whether the asserted claims covered the generic product or its proposed use.

The principal legal issues in an RXR agonist case would include:

Whether the generic active ingredient falls within a structure claim.
Whether the generic’s activity satisfies the RXR-over-RAR potency limitation.
Whether the proposed labeling induces infringement of a method-of-use claim.
Whether an asserted formulation claim covers the generic dosage form.
Whether the patent is invalid for lack of written description, enablement, anticipation, obviousness, or indefiniteness.

The patent’s expiration eliminates current infringement exposure under US 5,780,676. It does not eliminate possible historical damages disputes for conduct occurring before July 14, 2015.

How strong was the patent estate?

The patent estate was strongest against products that met both the chemical and functional limitations. Its commercial value came from the combination of:

Specific rexinoid structures.
Broad RXR-selectivity language.
Therapeutic indications spanning oncology, dermatology, lipid metabolism, and inflammation.
Combination therapy claims.
Potential coverage of oral, topical, enteral, and parenteral dosage forms.

Its principal vulnerabilities were the breadth of the functional claims and the need to prove receptor selectivity through a specified assay.

Strength factor	Assessment
Structure-specific protection	Stronger for the ten named compounds
Functional RXR claims	Broad but dependent on assay interpretation
Formulation protection	Limited; vehicle language is broad and technically undetailed
Method-of-use protection	Broad disease coverage, but dependent on therapeutic administration
Combination claims	Narrower; synergy claim imposes substantial proof requirements
Biosimilar relevance	Low; bexarotene is a small molecule, not a biologic
Current enforceability	None, because the patent expired
Historical generic barrier	Material before expiration
Manufacturing barrier	Limited from this patent alone; no detailed process claim appears in the supplied claims

What formulation patents protected RXR agonists?

The supplied claims do not contain detailed formulation technology. They cover a pharmaceutical vehicle suitable for administration, but they do not require:

A particular solvent system.
A specific particle size.
A solid dispersion.
A controlled-release matrix.
A liposomal carrier.
A particular capsule fill.
A topical emulsion or gel composition.

As a result, US 5,780,676 is primarily an active-ingredient and therapeutic-use patent, not a sophisticated formulation patent. Separate patents may have protected Targretin capsule formulations, topical gels, manufacturing processes, or specific dosing regimens. Those patents must be reviewed independently through the FDA Orange Book, USPTO records, and the relevant patent family.

How does the patent compare with competing RXR and retinoid estates?

Product or class	Receptor profile	Principal commercial or development use	Relationship to US 5,780,676
Bexarotene	Selective RXR agonist	Cutaneous T-cell lymphoma and oncology	Closest commercial RXR comparator
Alitretinoin	Agonist at RAR and RXR receptors	Dermatology and oncology research	Broader retinoid profile, less RXR-selective
Isotretinoin	Primarily retinoid pathway activity after metabolism	Acne	Not a direct RXR-selective substitute
Tazarotene	RAR-selective retinoid prodrug	Acne and psoriasis	Different receptor preference
Adapalene	Selective RAR-beta/RAR-gamma agonist	Acne and dermatology	Different receptor class preference
Experimental rexinoids	RXR-selective or RXR-biased activity	Oncology, metabolic disease, and dermatology research	Potentially relevant to functional claim scope

The patent’s competitive significance was greater for rexinoids than for conventional RAR-directed retinoids. A RAR-selective product would generally fall outside the core pharmacological concept unless it also satisfied the claimed RXR-over-RAR activity test.

What generic launch risks existed before expiration?

Before July 14, 2015, a generic applicant faced several potential launch pathways:

Paragraph III launch: wait until the patent expired.
Paragraph IV launch: challenge validity, enforceability, or infringement.
Noninfringing formulation: use a different formulation while avoiding relevant composition claims.
Different indication strategy: seek approval with labeling that omitted patented uses.
At-risk launch: launch before resolution of litigation, subject to damages and injunction exposure.

For capsules or topical products containing bexarotene, the key risks were not limited to chemical identity. They included induced infringement based on labeling, the scope of listed use claims, and whether the relevant product or use satisfied the RXR-selectivity limitations.

Today, the patent itself presents no US launch barrier. Current risk analysis would focus on later patents, regulatory exclusivity, product liability, manufacturing controls, and any jurisdiction where a corresponding patent had a different expiration date.

Does the patent create biosimilar risk?

No. Bexarotene is a small-molecule drug, so competitors use the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act. The relevant competitive products are generic drugs, not biosimilars.

What geographic rights did the patent provide?

US 5,780,676 provided rights only in the United States. Foreign patent rights would depend on separately issued national patents and their local status. Patent expiration, supplementary protection certificates, pediatric extensions, and regulatory exclusivities can differ by country.

A global RXR agonist freedom-to-operate review would therefore require separate analysis in:

United States.
European Patent Convention states.
Japan.
Canada.
Australia.
South Korea.
China.
Other jurisdictions where bexarotene or an RXR agonist was commercialized.

The US expiration date cannot be automatically applied to foreign counterparts.

Key Takeaways

US Patent 5,780,676 covers RXR-selective retinoid compositions, therapeutic methods, and combination treatments.
Claim 1 is limited to ten specified compounds and their pharmaceutically acceptable esters, amides, and salts.
Claims 2-18 use a functional receptor-activity test requiring greater RXR than RAR potency.
Claims 3, 4, 8, 9, 11, 12, 14, 15, 17, and 18 impose threefold or fivefold selectivity thresholds.
Claims 19-23 cover combinations with antiproliferative or cell-cycle-modulating agents, including interferon, methotrexate, fluorouracil, and cytarabine.
Bexarotene is the principal commercial RXR agonist associated with the field, but it is not expressly named in the supplied text of claim 1.
The patent expired July 14, 2015.
No current US Paragraph IV or biosimilar barrier arises from this expired patent.
The patent is primarily a chemical, receptor-function, and method-of-use patent rather than a detailed formulation or manufacturing patent.
Any current competitive threat analysis must focus on later patents and regulatory protections.

FAQs About US Patent 5,780,676

Does US 5,780,676 cover all RXR agonists?

No. Claim 1 covers ten named chemical structures and specified derivatives. The broader functional claims may reach additional compounds, but only if they satisfy the claimed RXR-over-RAR activity and therapeutic limitations.

Is bexarotene expressly listed in claim 1?

No. The supplied claim language does not expressly identify bexarotene by chemical name. Bexarotene coverage must be evaluated under the functional claims and the full patent record.

Can a generic manufacturer still be sued under US 5,780,676?

Not for post-expiration conduct based solely on this patent. The patent expired July 14, 2015. Historical conduct before expiration may raise separate damages issues.

Are the combination claims limited to cancer treatment?

The combination claims are directed to inhibition of abnormal cellular proliferation. Claim 23 identifies interferon, methotrexate, fluorouracil, and ARA-C, but the broader claims are not limited to a single cancer type.

Does the patent protect a specific capsule or gel formulation?

Not on the supplied claim language. The composition claims require a pharmaceutically acceptable vehicle but do not require a particular excipient system, release mechanism, particle size, or topical delivery technology.

References

United States Patent and Trademark Office. (1998). U.S. Patent No. 5,780,676: Retinoids and methods of use thereof. https://patents.google.com/patent/US5780676
U.S. Food and Drug Administration. (2018). Targretin (bexarotene) capsules and gel prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0637297	⤷ Start Trial	01C0027	France	⤷ Start Trial
European Patent Office	0637297	⤷ Start Trial	SPC013/2001	Ireland	⤷ Start Trial
European Patent Office	0637297	⤷ Start Trial	CA 2001 00032	Denmark	⤷ Start Trial
European Patent Office	0637297	⤷ Start Trial	C300054	Netherlands	⤷ Start Trial
European Patent Office	0637297	⤷ Start Trial	SPC/GB01/041	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,780,676

Summary for Patent: 5,780,676